Agree with this. I've also spoken to the company on the same basis. Kempler provided good historical context to the science and his involvement since inception, plus why they are approaching it the way they are, ie. to give it maximum chance of success. Phase 2 is fully funded with the $33m in bank, plus they receive a reasonable % back on R&D spend. Confident they have the right commercial and technical expertise to see this through.
Stock basically trading at cash value with no EV ascribed to assets, patents etc. With no shorts on this stock, selling appears to be tax related, people who have just given up or those that bought less than $5,000 worth thinking they can turn it into $100,000 in a few months.
Happy to keep buying from you!
Ann: Alterity to Present at Life Sciences Investor Forum, page-11
-
- There are more pages in this discussion • 11 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ATH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.5¢ |
Change
0.001(11.1%) |
Mkt cap ! $26.22M | |||
| Open | High | Low | Value | Volume |
| 0.5¢ | 0.5¢ | 0.5¢ | $4.263K | 916.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 58 | 69165915 | 0.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.5¢ | 38212524 | 21 |
View Market Depth
| Last trade - 15.11pm 05/07/2024 (20 minute delay) ? |
| ATH (ASX) Chart |